ClinicalTrials.gg

Program

leuprolide mesylate

Also written as “Leuprolide Mesylate” and “Leuprolide Injectable Emulsion (CAMCEVI®)”.

Its studies are mostly in Prostatic Neoplasms, led by 2 companies.

Furthest: phase 3, since Sep 1, 20143 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Foresee Pharmaceuticals20 open or runningphase 3since Sep 1, 2014Sep 1, 2014none ahead
Changchun GeneScience Pharmaceutical10 open or runningphase 3since May 11, 2025May 11, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 1, 2014First study: phase 3 study in Prostatic NeoplasmsNew to Foresee PharmaceuticalsForesee Pharmaceuticals · NCT02234115 · 137 enrolled · United States, Austria, Czechia and more
  2. Aug 19, 2017Phase 3 study in Prostatic NeoplasmsForesee Pharmaceuticals · NCT03261999 · 144 enrolled · United States, Czechia, Korea, Republic of and more
  3. May 11, 2025Changchun GeneScience Pharmaceutical’s first study: phase 3 study in Advanced Prostate CancerNew to Changchun GeneScience PharmaceuticalChangchun GeneScience Pharmaceutical · NCT06984159 · 137 enrolled · China

TargetBeta

GNRHR →read by rule
“Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule

Other programs on GNRHR

ProgramCompanyFurthest phaseStudies
LeuprolideruleTakedaphase 439
triptorelinruleIpsenphase 421
GoserelinruleAstraZenecaphase 414
linzagolixruleKissei Pharmaceuticalphase 314
GnRH Antagonist SHR7280Jiangsu HengRui Medicinephase 310
Gonadotropin-Releasing HormoneruleFerring Pharmaceuticalsphase 35

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06984159Advanced Prostate Cancer · China3CompletedChangchun GeneScience PharmaceuticalNov 30, 2023137
NCT03261999Prostatic Neoplasms · United States, Czechia, Korea, Republic of and more3CompletedForesee PharmaceuticalsNov 19, 2018144
NCT02234115Prostatic Neoplasms · United States, Austria, Czechia and more3CompletedForesee PharmaceuticalsAug 30, 2016137

How it is read

Names in the registry

  • “Leuprolide Mesylate”, 2 entries
  • “Leuprolide Injectable Emulsion (CAMCEVI®)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.